ERBB2 alteration with or without co-existent EGFR mutation in metastatic non-small cell lung cancer


Vijendra Singh, Yasmine Baca, Seongho Kim, Yanis Boumber, Hirva Mamdani, Edward S. Kim, Ammar Sukari, Chul Kim, Gerold Bepler, Stephen V. Liu, Alexander I. Spira, Hossein Borghai, Misako Nagasaka


For epidermal growth factor (EGFR) mutated non-small cell lung carcinoma (NSCLC) multiple EGFR tyrosine kinase inhibitors (TKIs) are approved. ERBB2 alteration (mutation and/or amplification) is associated with poor survival in NSCLS patients and is commonly reported as a resistance mechanism to EGFR TKIs.

Study Objectives

Investigate the prevalence of ERBB2 alteration with or without EGFR as a co-mutation in NSCLC. Describe type of ERBB2 mutation and EGFR mutation when both are present as co-mutation.


A minority of EGFR mutated NSCLC patients had ERBB2 alterations. ▪ In ERBB2 and EGFR co-mutated patients, exon 21 mutations for EGFR and exon 8 mutations for ERBB2 were common. ▪ Forty percent of patients who had exon 8 ERBB2 mutation had EGFR as a co-mutation.

Download Publication